Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy

Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy Invited Commentary Invited Commentary Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy Viridiana Kocaba, MD, PhD; Silke Oellerich, PhD; Gerrit R. J. Melles, MD, PhD Over the past decade, Descemet membrane endothelial 60 years included in the derivation cohort (mean age, 67 years; keratoplasty (DMEK) has become the standard for the treat- range, 57-77 years). In addition to including demographic, ment of endothelial diseases, with Fuchs endothelial corneal subjective, and optical parameters, a comprehensive model dystrophy (FECD) being the most common indication. Des- for predicting DMEK outcome in eyes with FECD should take cemet membrane endothe- the pathogenesis of the disease into account, as disease sever- ity may play an important role in predicting postoperative lial keratoplasty in eyes with Related article FECD usually results in suc- outcomes. cessful clinical outcomes with low postoperative complica- Over the past 2 decades, there have been substantial ad- tion rates. Because of the fast and reliable visual rehabilita- vances in understanding FECD pathogenesis. Fuchs endothe- tion after DMEK, the visual threshold for undergoing corneal lial corneal dystrophy is defined as a complex epigenetic dis- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy

Loading next page...
 
/lp/american-medical-association/toward-a-paradigm-shift-in-the-therapeutic-approach-to-fuchs-NfTyxoYgIq
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2020.7041
Publisher site
See Article on Publisher Site

Abstract

Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy Invited Commentary Invited Commentary Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy Viridiana Kocaba, MD, PhD; Silke Oellerich, PhD; Gerrit R. J. Melles, MD, PhD Over the past decade, Descemet membrane endothelial 60 years included in the derivation cohort (mean age, 67 years; keratoplasty (DMEK) has become the standard for the treat- range, 57-77 years). In addition to including demographic, ment of endothelial diseases, with Fuchs endothelial corneal subjective, and optical parameters, a comprehensive model dystrophy (FECD) being the most common indication. Des- for predicting DMEK outcome in eyes with FECD should take cemet membrane endothe- the pathogenesis of the disease into account, as disease sever- ity may play an important role in predicting postoperative lial keratoplasty in eyes with Related article FECD usually results in suc- outcomes. cessful clinical outcomes with low postoperative complica- Over the past 2 decades, there have been substantial ad- tion rates. Because of the fast and reliable visual rehabilita- vances in understanding FECD pathogenesis. Fuchs endothe- tion after DMEK, the visual threshold for undergoing corneal lial corneal dystrophy is defined as a complex epigenetic dis-

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Apr 18, 2021

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month